Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6604556 | 0.90 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL13875665 | 0.90 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL6135412 | 0.90 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL8078188 | 0.90 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL14364969 | 0.90 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL6135633 | 0.90 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL9185372 | 0.90 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL472020 | 0.90 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL9532928 | 0.77 | TACR1 (0.46) | TACR1 | |
| SCHEMBL9537788 | 0.77 | TACR1 (0.46) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342028-B2 | Medical use for tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2008-03-11 | — | — | US | disclosed |
| US-7342028-B2 | Medical use for tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2008-03-11 | — | — | US | disclosed |
| US-7214692-B2 | Medical use for tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-7214692-B2 | Medical use for tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-20030162766-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-6369074-B1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | PFIZER INC. | 2002-04-09 | — | — | US | disclosed |
| US-20010023248-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | HOWARD HARRY R (US) | 2001-09-20 | — | — | US | disclosed |
| EP-0806423-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists | PFIZER INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0675886-A1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-10-11 | — | — | EP | disclosed |
| WO-1994013663-A1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023248-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | NPY1R, OPRK1, OPRL1 | TACR1 5/4885CHRNB4 175/4885CHRNA3 70/4885 |
| US-20030162766-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | NPY1R, OPRK1, TACR1 | TACR1 3/4885CHRNB4 171/4885CHRNA3 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.